Yin Liu
270 Dong An Road
Shanghai, 200032, China
Shanghai, 200032, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 30 publications
Effect of adjuvant carboplatin intensified chemotherapy versus standard chemotherapy on survival in women with high risk, early stage, triple negative breast cancer (CITRINE): randomised, open label phase 3 trial.
Journal: BMJ (Clinical research ed.)
Published: December 23, 2025
Integrated analysis reveals the impact of obesity on triple-negative breast cancer.
Journal: Cancer letters
Published: November 06, 2025
Precision treatment with artificial intelligence assisted subtyping enhances therapeutic efficacy in HR+/HER2- breast cancer: The LINUXtrial.
Journal: Cancer cell
Published: March 08, 2025
Intensive chemotherapy versus standard chemotherapy among patients with high risk, operable, triple negative breast cancer based on integrated mRNA-lncRNA signature (BCTOP-T-A01): randomised, multicentre, phase 3 trial.
Journal: BMJ (Clinical research ed.)
Published: October 23, 2024
Stability and variability of molecular subtypes: comparative analysis of primary and metastatic triple-negative breast cancer.
Journal: Cancer biology & medicine
Published: May 16, 2024
Response to anti-HER2 neoadjuvant chemotherapy in HER2-positive invasive breast cancers with different HER2 FISH patterns.
Journal: Journal of clinical pathology
Published: July 15, 2023
Chemotherapy awakens dormant cancer cells in lung by inducing neutrophil extracellular traps.
Journal: Cancer cell
Published: July 03, 2023
Subtyping-based platform guides precision medicine for heavily pretreated metastatic triple-negative breast cancer: The FUTURE phase II umbrella clinical trial.
Journal: Cell research
Published: November 13, 2022
Nab-paclitaxel Followed by Dose-dense Epirubicin/Cyclophosphamide in Neoadjuvant Chemotherapy for Triple-negative Breast Cancer: A Phase II Study.
Journal: The oncologist
Published: June 28, 2022
Last Updated: 09/26/2026